Health Canada restricts Allergan’s Esmya
Health Canada has placed restrictions on Allergan’s uterine fibroid treatment Esmya, after discovering a possible link between its use and the risk of a rare but serious liver injury.
Read Moreby Anna Smith | Jan 15, 2019 | News | 0
Health Canada has placed restrictions on Allergan’s uterine fibroid treatment Esmya, after discovering a possible link between its use and the risk of a rare but serious liver injury.
Read Moreby Selina McKee | Feb 20, 2018 | News | 0
Doctors are not to prescribe Gedeon Richter’s Esmya for uterine fibroids in the UK while European regulators carry out a safety review of the drug.
Read Moreby Selina McKee | Jan 18, 2017 | News | 0
Allergan and Gedeon Richter are gearing up to file ulipristal acetate in the US in the second half of this year, in the hope of securing approval for the first oral treatment option for women suffering from uterine fibroids in the country.
Read Moreby Selina McKee | Aug 26, 2016 | News | 0
Women with uterine fibroids stand to gain routine access to a non-surgical treatment on the National Health Service for the first time, after cost regulators endorsed Gedeon Richter’s once-daily pill Esmya as an option.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
